Progressive Familial Intrahepatic Cholestasis (PFIC) — Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2021 To 2032
Progressive familial intrahepatic cholestasis (PFIC) is inherited condition that affects the liver. In PFIC, children are not able to drain bile from the liver even though the large bile ducts are open (cholestasis). Mutations in the ATP8B1, ABCB11, and ABCB4 genes cause PFIC1, PFIC2 and PFIC3, respectively. Some people with PFIC do not have a mutation in the ATP8B1, ABCB11, or ABCB4 gene.
- PFIC is estimated to affect 1 in 50,000 to 100,000 people worldwide. PFIC type 1 is much more common in the Inuit population of Greenland and the Old Order Amish population of the United States.
Thelansis’s “Progressive Familial Intrahepatic Cholestasis (PFIC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2021 To 2032” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Progressive Familial Intrahepatic Cholestasis (PFIC) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Progressive Familial Intrahepatic Cholestasis (PFIC) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Progressive Familial Intrahepatic Cholestasis (PFIC) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
